# Autoimmune and Inflammatory Disorders Research

**Type:** Topics  
**Canonical URL:** https://scholariq.org/topics/autoimmune-and-inflammatory-disorders-research/

## Facts

| Field | Value |
| --- | --- |
| Description | This cluster of papers focuses on hemophagocytic syndromes, particularly hemophagocytic lymphohistiocytosis (HLH) and related disorders such as macrophage activation syndrome. It covers topics including diagnostic guidelines, therapeutic approaches, genetic mutations, cytokine involvement, and treatment efficacy in both pediatric and adult patients with various forms of the syndrome. The cluster also explores the association of these syndromes with conditions like juvenile idiopathic arthritis and provides insights into the pathogenesis, classification criteria, and long-term outcomes. |
| Domain | Health Sciences |
| Field | Medicine |
| OpenAlex ID | t11616 |
| Works | 272 |

## Topic papers all

Showing 15 of 272.

- [EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update](https://scholariq.org/papers/eular-recommendations-for-the-management-of-rheumatoid-arthritis-with-synthetic/)
- [Infliximab and Methotrexate in the Treatment of Rheumatoid Arthritis](https://scholariq.org/papers/infliximab-and-methotrexate-in-the-treatment-of-rheumatoid-arthritis/)
- [Rheumatoid arthritis](https://scholariq.org/papers/rheumatoid-arthritis/)
- [STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD](https://scholariq.org/papers/stride-ii-an-update-on-the-selecting-therapeutic-targets-in-inflammatory-bowel/)
- [Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease](https://scholariq.org/papers/genome-wide-association-defines-more-than-30-distinct-susceptibility-loci-for/)
- [Anti-TNF Antibody Therapy in Rheumatoid Arthritis and the Risk of Serious Infections and Malignancies](https://scholariq.org/papers/anti-tnf-antibody-therapy-in-rheumatoid-arthritis-and-the-risk-of-serious/)
- [Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial](https://scholariq.org/papers/infliximab-chimeric-anti-tumour-necrosis-factor-monoclonal-antibody-versus/)
- [Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: Part I](https://scholariq.org/papers/estimates-of-the-prevalence-of-arthritis-and-other-rheumatic-conditions-in-the-2/)
- [2019 update of the EULAR recommendations for the management of systemic lupus erythematosus](https://scholariq.org/papers/2019-update-of-the-eular-recommendations-for-the-management-of-systemic-lupus/)
- [Fibroblast‐like synoviocytes: key effector cells in rheumatoid arthritis](https://scholariq.org/papers/fibroblast-like-synoviocytes-key-effector-cells-in-rheumatoid-arthritis/)
- [The PREMIER study: A multicenter, randomized, double‐blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment](https://scholariq.org/papers/the-premier-study-a-multicenter-randomized-double-blind-clinical-trial-of/)
- [Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: Results of a multicenter, randomized, double‐blind, placebo‐controlled, phase III trial evaluating primary efficacy and safety at twenty‐four weeks](https://scholariq.org/papers/rituximab-for-rheumatoid-arthritis-refractory-to-anti-tumor-necrosis-factor/)
- [Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor ? monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis](https://scholariq.org/papers/therapeutic-efficacy-of-multiple-intravenous-infusions-of-anti-tumor-necrosis/)
- [\nEULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs.](https://scholariq.org/papers/neular-recommendations-for-the-management-of-rheumatoid-arthritis-with-synthetic/)
- [2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups](https://scholariq.org/papers/2017-european-league-against-rheumatism-american-college-of-rheumatology/)

## Topic primary papers

Showing 15 of 64.

- [Adult haemophagocytic syndrome](https://scholariq.org/papers/adult-haemophagocytic-syndrome/)
- [Recommendations for the management of hemophagocytic lymphohistiocytosis in adults](https://scholariq.org/papers/recommendations-for-the-management-of-hemophagocytic-lymphohistiocytosis-in/)
- [Restoring synovial homeostasis in rheumatoid arthritis by targeting fibroblast-like synoviocytes](https://scholariq.org/papers/restoring-synovial-homeostasis-in-rheumatoid-arthritis-by-targeting-fibroblast/)
- [2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative](https://scholariq.org/papers/2016-classification-criteria-for-macrophage-activation-syndrome-complicating/)
- [Proposal for a New Set of Classification Criteria for Adult-Onset Still Disease](https://scholariq.org/papers/proposal-for-a-new-set-of-classification-criteria-for-adult-onset-still-disease/)
- [Immunopathogenesis and treatment of cytokine storm in COVID-19](https://scholariq.org/papers/immunopathogenesis-and-treatment-of-cytokine-storm-in-covid-19/)
- [Dense genotyping of immune-related disease regions identifies 14 new susceptibility loci for juvenile idiopathic arthritis](https://scholariq.org/papers/dense-genotyping-of-immune-related-disease-regions-identifies-14-new/)
- [2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis](https://scholariq.org/papers/2016-classification-criteria-for-macrophage-activation-syndrome-complicating-2/)
- [Clinical similarities and differences of patients with X-linked lymphoproliferative syndrome type 1 (XLP-1/SAP deficiency) versus type 2 (XLP-2/XIAP deficiency)](https://scholariq.org/papers/clinical-similarities-and-differences-of-patients-with-x-linked/)
- [A genetic association between juvenile rheumatoid arthritis and a novel interleukin‐1α polymorphism](https://scholariq.org/papers/a-genetic-association-between-juvenile-rheumatoid-arthritis-and-a-novel/)
- [The diagnostic significance of soluble CD163 and soluble interleukin‐2 receptor α‐chain in macrophage activation syndrome and untreated new‐onset systemic juvenile idiopathic arthritis](https://scholariq.org/papers/the-diagnostic-significance-of-soluble-cd163-and-soluble-interleukin-2-receptor/)
- [Proinflammatory cytokine profiles in sera and pathological tissues of patients with active untreated adult onset Still's disease.](https://scholariq.org/papers/proinflammatory-cytokine-profiles-in-sera-and-pathological-tissues-of-patients/)
- [Evidence of the transient nature of the Th17 phenotype of CD4+CD161+ T cells in the synovial fluid of patients with juvenile idiopathic arthritis](https://scholariq.org/papers/evidence-of-the-transient-nature-of-the-th17-phenotype-of-cd4-cd161-t-cells-in/)
- [2022 American College of Rheumatology Guideline for Vaccinations in Patients With Rheumatic and Musculoskeletal Diseases](https://scholariq.org/papers/2022-american-college-of-rheumatology-guideline-for-vaccinations-in-patients/)
- [Macrophage polarization in rheumatoid arthritis: signaling pathways, metabolic reprogramming, and crosstalk with synovial fibroblasts](https://scholariq.org/papers/macrophage-polarization-in-rheumatoid-arthritis-signaling-pathways-metabolic/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.